Achieve Life Sciences Inc

Achieve Life Sciences (ACHV) stocks hit a 200‑day moving‑average milestone amid a bullish trend, yet still face negative earnings and a high P/B ratio. Explore what this means for investors.

Achieve Life Sciences shares surged after Hunterbrook Capital’s bullish endorsement, highlighting the firm’s cytisine nicotine‑addiction pipeline and its potential for U.S. approval and growth.

Achieve Life Sciences Inc. has made significant strides in its mission to combat nicotine addiction, with a proposed public offering, partnership with Omnicom, and FDA submission for its cytisinicline treatment.

Achieve Life Sciences reported a GAAP EPS of -$0.37 for Q1 2025, aligning with expectations, as the company focuses on developing and commercializing its cytisinicline program for nicotine addiction.